Shareholders back Pharma-Bio Serv (PBSV) director and auditor at 2026 meeting
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Pharma-Bio Serv, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected Irving Wiesen as a Class I director to serve until the 2029 Annual Meeting, with 10,208,071 votes for and 195,625 votes withheld, plus 2,839,645 broker non-votes. Stockholders also ratified the selection of Crowe PR PSC as independent certified public accountants for the fiscal year ending October 31, 2026, with 13,241,794 votes for, 3 against and 1,544 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 9.01 — Financial Statements and Exhibits
1 item
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Votes for director: 10,208,071 votes
Votes withheld for director: 195,625 votes
Broker non-votes on director election: 2,839,645 votes
+3 more
6 metrics
Votes for director
10,208,071 votes
Votes for Irving Wiesen as Class I director
Votes withheld for director
195,625 votes
Votes withheld on Irving Wiesen election
Broker non-votes on director election
2,839,645 votes
Director election proposal broker non-votes
Votes for auditor ratification
13,241,794 votes
Ratification of Crowe PR PSC for FY ending Oct 31, 2026
Votes against auditor ratification
3 votes
Opposed Crowe PR PSC ratification
Abstentions on auditor ratification
1,544 votes
Abstained on Crowe PR PSC ratification proposal
Key Terms
Annual Meeting of Stockholders, broker non-votes, independent certified public accountants, Emerging growth company
4 terms
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."
broker non-votes financial
"There were 2,839,645 broker non-votes on this proposal."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent certified public accountants financial
"Crowe PR PSC as the Company's independent certified public accountants"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
How many votes did Irving Wiesen receive in the Pharma-Bio Serv (PBSV) director election?
Irving Wiesen received 10,208,071 votes for and 195,625 votes withheld. There were also 2,839,645 broker non-votes recorded on this proposal, and he was elected as a Class I director to serve until the 2029 Annual Meeting of Stockholders.
Was the auditor ratification for Pharma-Bio Serv (PBSV) approved at the 2026 meeting?
Yes, shareholders ratified Crowe PR PSC as independent certified public accountants. The proposal received 13,241,794 votes for, 3 votes against and 1,544 abstentions, with no broker non-votes reported on this ratification item for the 2026 fiscal year.
What is the term length for Pharma-Bio Serv (PBSV) director Irving Wiesen?
Irving Wiesen was elected as a Class I director to serve until the 2029 Annual Meeting of Stockholders. He will continue in this role until that meeting or until his successor is duly elected and qualified, consistent with the company’s governance structure.